

FOR IMMEDIATE RELEASE:

Morphogenesis, Inc. Receives Patent on Immunotherapy for Cancer

March 25, 2008, Tampa, Florida — Morphogenesis, Inc. received a US Patent (7,348,015) today, entitled “Antigen modified cancer cell vaccines for cancer therapy.” This patent is the second in a series of patents expected to be approved by the US patent office has been issued.

“This vaccine is little out of the ordinary,” said Company spokesperson and CEO of Morphogenesis, Pat Lawman, PhD, “in that it was designed as a way to treat cancer. The vaccine, dubbed ImmuneFx™, was developed by engineering cancer cells to express antigens capable of inducing tumor-protective immunity. The modified cancer cells are highly immunogenic to the host and can be administered to patients suffering from the cancer as a therapeutic vaccine.”

All cells in our body have unique proteins or markers on their surface called *antigens*, and many cancer cells make tumor-specific antigens. Unfortunately, sometimes tumor antigens are “hidden” from the immune system and the body is unable to make an effective immune response against what it recognizes as “self”. When this happens, tumors are said to escape immune surveillance. The goal of cancer immunotherapy and cancer vaccines, in particular, is to teach the immune system to recognize these cancer-specific antigens and then reject any cell which bears them.

Normally, foreign antigens are recognized by antigen presenting cells, which then activate other white blood cells, called B lymphocytes and T lymphocytes. B lymphocytes produce antibodies that recognize a particular antigen and bind to it, helping to destroy the cancer cells. On the other hand, T lymphocytes attack and kill the cancer cells directly. Thus, says, Dr. Lawman, “The optimum strategy is to design an immunotherapy which makes tumors appear “foreign,” so the immune system will recognize them as dangerous and using both arms of the immune response, eradicate the malignant cells.” The ImmuneFx cancer vaccine has been shown to induce both types of immune response in pre-clinical studies with neuroblastoma and in clinical veterinary studies with dogs treated for late-stage multi-centric lymphoma.

The Company plans to pursue regulatory approval from the FDA for use of the vaccine in humans and from the USDA for veterinary applications.”We are very excited to take this therapy into the veterinary field. It is estimated that 1 in 2 dogs will develop cancer and that 1 in 4 will die of it. Hopefully, the ImmuneFx vaccine will be able to provide a potential cure for our ‘best friends’ without the harsh side-effects of conventional therapies,” added Dr. Lawman.

ABOUT MORPHOGENESIS:

Morphogenesis is a privately-held biotechnology company which specializes in cell therapy. The Company is also developing proprietary stem cell products, including its prototype cell separation device, which was completed earlier this month. For more information about Morphogenesis, contact Dr. Lawman at 813 855 9844 or log onto www.morphogenesis-inc.com.

Forward-Looking Statements:

Statements in this press release that are not strictly historical may be “forward-looking” statements, which involve risks and uncertainties. There can be no assurance that Morphogenesis, Inc. will be able to commercially develop cancer vaccine therapy, cell separation device or stem cell products; that the proposed products will prove to be safe and/or effective, that any clinical trials will be successful, or that necessary regulatory approvals will be obtained.

Morphogenesis, Inc. | 209 State Street | Oldsmar, FL 34677
Telephone: (813) 855-9844 | Fax: (813) 854-2340 | email: plawman@morphogenesis-inc.com